REAL-WORLD OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND SUBSTANCE ABUSE DISORDERS TREATED WITH GLECAPREVIR/PIBRENTASVIR FOR 8 WEEKS: A POOLED ANALYSIS OF MULTINATIONAL POST-MARKETING OBSERVATIONAL STUDIES

Rizzardini G1, Gschwantler M2, Bourgeois S3, Müllhaupt B4, Mazur W5, Bondin M6, Zhang ZZ6, Marra F7, Veitsman E8, Mimidis K9, Marques N10, Foucher J11

11st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy, 2Department of Internal Medicine IV, Wilhelminenspital, Vienna, Austria, 3Stuivenberg ZNA, Antwerp, Belgium, 4Department of Gastroenterology and Hepatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland, 5Clinical Department of Infectious Diseases, Medical University of Silesia, Katowice, Poland, 6AbbVie, Inc., North Chicago, Illinois, USA, 7Liver Unit, Rambam Health Care Campus, Haifa, Israel, 8University of Liverpool Hepatology Drug Interactions Group, Liverpool, UK, 9First Department of Internal Medicine, Democritus University of Thrace Medical School, Alexandroupolis, Greece, 10Infectious Diseases Service, Hospital Garcia de Orta EPE, Almada, Portugal, 11Hôpital du Haut-Lévêque, Pessac, France

Background: Hepatitis C virus (HCV) affects >50% of people who inject drugs. To meet World Health Organization 2030 HCV elimination targets, people who use drugs (PWUD) are a critical population to reach and provide access to treatment. Glecaprevir/pibrentasvir (G/P) is approved for treatment of adults with chronic HCV genotype (GT)1–6 infection, with a label now including 8-week treatment for treatment-naïve (TN) patients with compensated cirrhosis (CC). Despite data demonstrating G/P effectiveness in PWUD, barriers to treatment persist, including stigma, risk of reduced treatment compliance, and thus, effectiveness. Shorter therapy durations could potentially improve outcomes in such patients. This analysis examined the real-world effectiveness and safety of 8-week G/P in PWUD and other historically underserved patient groups.

Methods: Data from TN patients (without cirrhosis/with CC) prescribed 8-week G/P were pooled from 9 countries (13 Nov 2017–02 Oct 2019). The percentage of patients who achieved sustained virologic response at post-treatment Week 12 (SVR12) was assessed overall/by subgroup. Illicit drug use was patient reported.

Results: Of 1423 patients prescribed G/P for 8 weeks, 452 (31.8%) had a self-reported history of any illicit drug use (PWUD), 120 (8.4%) had psychiatric disorders, 192 (13.5%) had a history of alcohol use (≥2 drinks/day), 363 (25.5%) were unemployed, 312 (21.9%) reported low-to-no education. The most commonly used prescribed psychotropic drugs with a potential interaction with G/P were quetiapine (0.5%), haloperidol (0.3%), and aripiprazole (0.3%). The most commonly used illicit drugs in PWUD were heroin (58.7%), cocaine (22.8%), and marijuana (12.8%). SVR12 rate was 98.1% (1198/1221) overall, 97.0% (357/368) in PWUD and ≥95.6% across subgroups (Figure). There was 1 G/P-related serious adverse event.
**Conclusion:** Across a variety of real-world clinical settings, 8-week G/P treatment was highly effective and well tolerated in HCV-infected PWUD and other historically underserved patients.

Error bars represent 95% confidence intervals. Data are from the core population with sufficient follow-up.

*An additional 4 TN/TE patients taking quetiapine received G/P for 12 weeks; all (100%) achieved SVR12. †An additional 22 TN/TE patients taking cocaine received G/P for 12 weeks; all (100%) achieved SVR12. ‡An additional 44 TN/TE patients taking heroin received G/P for 12 weeks; all (100%) achieved SVR12. §An additional 10 TN/TE patients taking marijuana received G/P for 12 weeks; all (100%) achieved SVR12.

PWUD, people who use drugs; SVR12, sustained virologic response at post-treatment Week 12; TE, treatment-experienced; TN, treatment-naïve.

**Disclosure of Interest Statement:**

**Rizzardini G:** Paid consultant: AbbVie, Angelini, Bristol-Myers Squibb, Gilead, MSD, and ViiV; Research funding through ASST Fatebenefratelli-Sacco University Hospital: AbbVie, Gilead, MSD, and ViiV Healthcare

**Gschwantler M:** Advisory board member and speaker: AbbVie, Gilead, Janssen, and MSD; Grants: AbbVie, Gilead, and MSD

**Bourgeois S:** Advisory board member and speaker’s bureau: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and MSD

**Müllhaupt B:** Advisory board member and speaker: AbbVie and Gilead; Grants: Gilead

**Mazur W:** Lecture fees: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche; Research funding: AbbVie, Gilead, Merck, and Roche; Consultancy: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche

**Bondin M:** Employee of AbbVie and may hold stock/share options

**Zhang ZZ:** Employee of AbbVie and may hold stock/share options

**Marra F:** Received speaking and teaching fees: AbbVie, Gilead, MSD and ViiV Healthcare

**Veitsman E:** Advisory board member and speaker: AbbVie, Gilead
Mimidis K: Advisory board member and speaker: AbbVie, Gilead, and MSD; Grants: AbbVie and MSD
Marques N: Advisory board: MSD, Gilead, Janssen, AbbVie, and Viiv Healthcare
Foucher J: Advisory board member and speaker: AbbVie, Gilead, Intercept, and MSD

Acknowledgments: AbbVie sponsored the study, contributed to its design, and participated in the collection, analysis, and interpretation of the data and in the writing, review, and approval of the abstract. All authors had access to relevant data, and participated in the writing, review, and approval of the abstract. Glecaprevir was identified by AbbVie and Enanta.
Medical writing support was provided by Heather Shawcross, PhD, and Brandy Menges, PhD, of Fishawack Communications Ltd, funded by AbbVie